Principal Securities’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Principal Securities's XBI Position: Q1 2026 in Review
Principal Securities increased its State Street SPDR S&P Biotech ETF (XBI) stake by 2.3% in Q1 2026, buying an estimated $20K and bringing the position to 7,111 shares worth $908K. The position accounts for 0.01% of the portfolio, ranked #754.
Principal Securities first reported a position in XBI in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.1M in Q1 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Principal Securities held 7,111 shares of State Street SPDR S&P Biotech ETF worth $908K as of Q1 2026.
- Principal Securities bought 160 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $20K.
- State Street SPDR S&P Biotech ETF made up 0.01% of Principal Securities's portfolio in Q1 2026, its #754 holding.
- Principal Securities first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and has held it in 10 quarters since.
- Principal Securities's State Street SPDR S&P Biotech ETF position peaked at $1.1M in Q1 2025.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Principal Securities's 13F filing for Q1 2026, filed 13 May 2026.